384 related articles for article (PubMed ID: 33338862)
21. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
Dierks C; Seufert J; Aumann K; Ruf J; Klein C; Kiefer S; Rassner M; Boerries M; Zielke A; la Rosee P; Meyer PT; Kroiss M; Weißenberger C; Schumacher T; Metzger P; Weiss H; Smaxwil C; Laubner K; Duyster J; von Bubnoff N; Miething C; Thomusch O
Thyroid; 2021 Jul; 31(7):1076-1085. PubMed ID: 33509020
[No Abstract] [Full Text] [Related]
22. Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis.
Zhu C; Ma X; Hu Y; Guo L; Chen B; Shen K; Xiao Y
Oncotarget; 2016 Jul; 7(28):44545-44557. PubMed ID: 27329593
[TBL] [Abstract][Full Text] [Related]
23. A single-institution retrospective exploratory analysis on the effectiveness and safety of lenvatinib plus pembrolizumab for advanced endometrial cancer: insights from ProMisE molecular classification system.
Chiba Y; Kagabu M; Osakabe M; Ito R; Sato S; Takatori E; Kaido Y; Nagasawa T; Shoji T; Yanagawa N; Baba T
Jpn J Clin Oncol; 2024 Apr; 54(4):424-433. PubMed ID: 38251744
[TBL] [Abstract][Full Text] [Related]
24. Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE-775.
Yonemori K; Yunokawa M; Ushijima K; Sakata J; Shikama A; Minobe S; Usami T; Enomoto T; Takehara K; Hasegawa K; Yamagami W; Yamamoto K; Han S; Dutta L; Orlowski R; Miura T; Makker V; Fujiwara K
Cancer Sci; 2022 Oct; 113(10):3489-3497. PubMed ID: 35612971
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis.
Jiang Q; Huang J; Zhang B; Li X; Chen X; Cui B; Li S; Guo G
Front Immunol; 2022; 13():801909. PubMed ID: 35309350
[TBL] [Abstract][Full Text] [Related]
26. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ; Porta C; Eto M; Powles T; Grünwald V; Hutson TE; Alekseev B; Rha SY; Merchan J; Goh JC; Lalani AA; De Giorgi U; Melichar B; Hong SH; Gurney H; Méndez-Vidal MJ; Kopyltsov E; Tjulandin S; Gordoa TA; Kozlov V; Alyasova A; Winquist E; Maroto P; Kim M; Peer A; Procopio G; Takagi T; Wong S; Bedke J; Schmidinger M; Rodriguez-Lopez K; Burgents J; He C; Okpara CE; McKenzie J; Choueiri TK;
J Clin Oncol; 2024 Apr; 42(11):1222-1228. PubMed ID: 38227898
[No Abstract] [Full Text] [Related]
27. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
28. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer.
How JA; Patel S; Fellman B; Lu KH; Hwu P; Ramondetta LM; Westin SN; Fleming ND; Soliman PT; Jazaeri AA
Gynecol Oncol; 2021 Jul; 162(1):24-31. PubMed ID: 33958211
[TBL] [Abstract][Full Text] [Related]
29. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Lenvatinib in Anaplastic Thyroid Carcinoma: A Meta-Analysis.
Huang D; Zhang J; Zheng X; Gao M
Front Endocrinol (Lausanne); 2022; 13():920857. PubMed ID: 35846304
[TBL] [Abstract][Full Text] [Related]
31. The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors.
Sun W; Yin X; Liu X; Wei J; Yu M; Li W; Ding X; Chen J
Front Immunol; 2024; 15():1380477. PubMed ID: 38698848
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy.
Dioun S; Chen L; De Meritens AB; St Clair CM; Hou JY; Khoury-Collado F; Pua T; Hershman DL; Wright JD
Gynecol Oncol; 2024 Mar; 182():70-74. PubMed ID: 38262241
[TBL] [Abstract][Full Text] [Related]
33. Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden.
Ralph L; Young K; Upadhyay N; Prabhu VS; Ljungcrantz C; Massaad R; Xu R; Giertz A; Merchant A; Orlowski R; Duska L
J Med Econ; 2024; 27(1):483-491. PubMed ID: 38470404
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors.
Al-Toubah T; Schell MJ; Morse B; Haider M; Valone T; Strosberg J
ESMO Open; 2024 Apr; 9(4):102386. PubMed ID: 38507897
[TBL] [Abstract][Full Text] [Related]
35. Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab.
Motzer R; George S; Merchan JR; Hutson TE; Song X; Perini RF; Xie R; Bapat U; Puente J
Oncologist; 2023 Jun; 28(6):501-509. PubMed ID: 36866412
[TBL] [Abstract][Full Text] [Related]
36. Atezolizumab Plus Bevacizumab Versus Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Lu J; Lin X; Teng H; Zheng Y
J Clin Pharmacol; 2024 Jun; 64(6):643-651. PubMed ID: 38311835
[TBL] [Abstract][Full Text] [Related]
37. Combined use of pembrolizumab and lenvatinib: A review.
Eisinger C; Muluneh B
J Oncol Pharm Pract; 2023 Sep; 29(6):1461-1466. PubMed ID: 37231712
[TBL] [Abstract][Full Text] [Related]
38. Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma.
Grünwald V; Larkin J; Puente J; Bedke J; Porta C
Clin Genitourin Cancer; 2024 Apr; 22(2):394-401. PubMed ID: 38218660
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of anti-PD-1 monotherapy
Liu Q; Li R; Li L; Wang G; Ji S; Zheng X; Jia X; Tao H; Hu Y
Ther Adv Med Oncol; 2023; 15():17588359231206274. PubMed ID: 37885459
[TBL] [Abstract][Full Text] [Related]
40. Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study.
Eto M; Takagi T; Kimura G; Fukasawa S; Tamada S; Miura Y; Oya M; Sassa N; Anai S; Nozawa M; Sakai H; Perini R; Yusa W; Ikezawa H; Narita T; Tomita Y
Cancer Med; 2023 Mar; 12(6):6902-6912. PubMed ID: 36457273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
